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A B S T R A C T
Purpose
To develop more evidence-based guidelines for the frequency of patient follow-up after treatment
of localized (American Joint Committee on Cancer [AJCC] stage I or II) melanoma.
Methods
We used data from Melanoma Institute Australia on an inception cohort of 3,081 consecutive
patients first diagnosed with stage I or II melanoma between January 1985 and December 2009.
Kaplan-Meier curves and Cox models were used to characterize the time course and predictors for
recurrence and new primaries. We modeled the delay in diagnosis of recurrence or new primary
as well as the number of monitoring visits required using two monitoring schedules: first,
according to 2008 Australian and New Zealand guidelines and, second, with fewer visits,
especially for those at lowest risk of recurrence.
Results
For every 1,000 patients beginning follow-up, 229 developed recurrence and 61 developed new
primary within 10 years. There was only a small difference in modeled delay in diagnosis (extra
44.9 and 9.6 patients per 1,000 for recurrence and new primary, respectively, with delay greater
than 2 months) using a schedule that requires far fewer visits (3,000 fewer visits per 1,000
patients) than recommended by current guidelines. AJCC substage was the most important
predictor of recurrence, whereas age and date of primary diagnosis were important predictors of
developing new primary.
Conclusion
By providing less intensive monitoring, more efficient follow-up strategies are possible. Fewer
visits with a more focused approach may address the needs of patients and clinicians to detect
recurrent or new melanoma.
J Clin Oncol 29:4641-4646. © 2011 by American Society of Clinical Oncology
INTRODUCTION
The cost of regular follow-up after treatment of
American Joint Committee on Cancer (AJCC)
stage I or II melanoma has been estimated at
between $441 to $628 per person per year (2004
Medicare fee reimbursement schedule) in the
United States.1 On the basis of 2007 estimates,2
there are approximately 800,000 people with a
past diagnosis of melanoma living in the United
States; their follow-up represents an important
burden to the US health care system, up to $500
million per year. Additionally, there is a lack of
evidence for the frequency and benefit of follow-up
visits after treatment for cancer.3,4
Melanoma guidelines typically recommend
follow-up for patients treated for localized disease
(stage I or II). This recommendation is generally
based on expert opinion, with monitoring schedules
informed by observed recurrence rates for patients
categorized into prognostic subgroups.5,6 Develop-
ment of new primaries is not usually considered,
although their detection is an aim of monitoring,5
nor are the benefits and harms of the proposed
monitoring schedule. Given that approximately
75% of patients detect their own recurrences,3,7 and
approximately 50% detect their own second prima-
ries,8 follow-up visits currently may be scheduled
more frequently than is necessary, with possible in-
efficient use of health resources and an unnecessary
burden on patients. Recently, a less frequent moni-
toring schedule was proposed9 based on an analysis
of recurrences in AJCC subgroups IA, IB, IIA, IIB,
and IIC in a group of patients undergoing follow-up
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at Melanoma Institute Australia (MIA; formerly the Sydney Mela-
noma Unit). A modification of this schedule comprises the experi-
mental arm of a randomized trial currently under way, in which the
less frequent monitoring schedule will be compared with a conven-
tional follow-up schedule from Dutch national guidelines.10
This study aims primarily to relate the estimated delay in diagno-
sis of recurrence or second primary in patients with localized stage I or
II cutaneous melanoma to the number of visits needed by two differ-
ent monitoring schedules. Secondarily, we estimated the effect of
prognostic factors on development of recurrence or second pri-
mary tumor.
METHODS
Study Design and Sample
All patients in the MIA database treated for invasive primary cutaneous
melanoma who were diagnosed by excision biopsy between January 1, 1985,
and December 31, 2009, and had AJCC stage I or II disease were considered for
the study. Patients were excluded if they did not have MIA-reviewed pathol-
ogy, were node positive (either by sentinel lymph node biopsy [SLNB] or
elective lymph node dissection), had insufficient data to allow substaging of
their disease, or had missing data on primary diagnosis date or last follow-up
date. Ethics approval was not required for this study.
Measurement of Risk Factors
All patients had wide local excision of primary melanoma after diagnos-
tic biopsy.9 Treatment of regional lymph nodes was categorized as SLNB,
elective lymph node dissection, or observation. Breslow thickness, ulceration,
mitotic rate, and Clark level of invasion (if mitotic rate was unknown) were
used to classify patient primaries into AJCC substages using the 2009 up-
dated criteria.11
Follow-Up and Outcome Events
Data were analyzed separately for development of recurrence and devel-
opment of new primary (results of analysis of composite outcome, recurrence,
or new primary are presented in Appendix, online only). Recurrence was
defined as the first abnormality diagnosed by histopathology (including cytol-
ogy) or imaging confirming the presence of metastatic disease. Diagnosis of
second primary melanoma required diagnostic biopsy and histopathology.
When a patient had both recurrence and second primary, we used whichever
occurred first as the outcome, and the patient was censored at this time for
analysis of the alternate outcome.
Follow-up visits entailed at least a medical history and clinical examina-
tion. The general follow-up schedule for patients during the study timeframe is
provided in the Appendix (online only). In addition to scheduled visits, all
patients could initiate visits if they were concerned they had recurrence or
new primary.
Statistical Analysis
All risk factors were included in multivariable Cox proportional hazard
models predicting time to recurrence and second primary. Data on disease-
free survival were considered censored for patients who were free from recur-
rence or new primary at last follow-up or at 10-year follow-up, whichever was
earlier. Likelihood-ratio tests were used to assess significance. Proportional
hazards assumptions were checked using Schoenfeld residuals. Analysis of
sensitivity to competing risks was also performed.
We assessed delay in the diagnosis of recurrence or new primary and
number of visits for two different monitoring schedules over 10 years of
follow-up. The two schedules were as follows:
Schedule one. On the basis of 2008 Australian and New Zealand guide-
lines,5 schedule one involved follow-up every 6 months for 5 years, then
annually for 5 years (patients with stages IA and IB disease) or every 3 months
for 5 years, then annually for 5 years (stages IIA, IIB, and IIC).
Schedule two. On the basis of recommendations of a previous report9
and modification of the experimental arm of MELFO (Melanoma
Follow-up Study),4 schedule two involved follow-up annually for 10 years
(stage I); every 6 months for 2 years, then annually for 8 years (stage IIA);
or every 4 months for 2 years, every 6 months during year 3, then annually
for 5 years (stages IIB and IIC).
Both schedules included a 1-month follow-up visit. We modeled the
theoretic number of patients experiencing a delay in diagnosis greater than 1, 2,
3, 6, 9, and 12 months, as a rate per 1,000 patients starting follow-up, for two
clinical scenarios. In the first scenario (only scheduled visits), we assumed any
diagnosis would be made at a scheduled visit. For the second scenario (sched-
uled and unscheduled visits), we assumed 75% of recurrences and 50% of new
primaries would be detected by the patient or partner with no delay in diag-
nosis, and all patients would seek clinical attention by a maximum of 3 months
for recurrence and 6 months for new primaries. Bootstrap random samples
were used to estimate 95% CIs and select patients who self-detected. Detailed
methods and a sensitivity analysis on the proportion of self-detecting patients
are presented in the Appendix (online only). For each monitoring schedule, we
calculated the number of visits required per 1,000 patients starting follow-up
until time of diagnosis of recurrence or new primary, time of loss to follow-up,
or a period of 10 years of follow-up.
RESULTS
A total of 3,081 patients with AJCC stage I or II disease were initially
included. We excluded 83 patients from analysis for whom it was not
possible to obtain information on the last clinic consultation at which
they were clear of disease or date of recurrence, when recurrence was
known to have occurred. Of the 2,998 patients remaining, 201 (6.7%)
died as a result of other causes without developing recurrence or new
primary, and their follow-up time was censored at their last recorded
follow-up visit, and 28 (0.9%) experienced recurrence but had no
recorded date of recurrence and were censored at the last follow-up
visit when they were free from melanoma.
Clinical characteristics of the 2,998 patients are presented in
Table 1; their median length of follow-up, censored at date of recur-
rence or new primary where applicable, was 2.7 years (range, 0 to 24.7
years). Altogether, 2,036 patients (67.9%) experienced follow-up of
fewer than 5 years because of diagnosis of recurrence or new primary,
loss to follow-up, or first primary diagnosis later than December 31,
2004, and 2,553 (85.2%) experienced follow-up of fewer than 10 years.
A substantial proportion of patients (799 of 2,998 patients; 27%) were
diagnosed within the last 10 years (diagnosed after December 31,
1999), and their follow-up is bounded by the end of the study period
(ie, uninformative censoring). For patients diagnosed before 2000 and
with no recurrence or new primary, the last recorded follow-up visit
was before 10 years of follow-up in 68% to 75% of patients, depending
on stage.
Recurrence and New Primary Over Time
Kaplan-Meier curves for time to recurrence stratified by AJCC
substage show higher recurrence rates in the first 5 years of follow-up
(particularly first year) and lower rates in the subsequent 5 years (Fig
1). New primary melanoma rates within each age group seemed to be
fairly constant throughout the 10-year period (Appendix Fig A1, on-
line only).
Prognostic Model
Two patients who had missing covariate information were
excluded from the Cox model, leaving 2,996 patients. For time to
recurrence, there was evidence of violation of the proportional
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hazards assumption using the whole 10-year follow-up period.
Therefore, we built separate models for three periods of follow-up:
recurrence within first year of follow-up (P  0.78 for test of
proportional hazards assumption), within 1 to 5 years (P  .28),
and within 5 to 10 years (P  .96). Within the first year, active
management of regional lymph nodes protected against early re-
currence, whereas increasing AJCC stage predicted increasing risk
of early recurrence (P  .001 for both; Table 2). Risk was especially
high for patients with stages IIB and IIC disease. There was also
evidence of modestly increased risk of recurrence for individuals
with primary located on the trunk, head, or neck (hazard ratio
[HR], 1.45; P  .016). In the period of 1 to 5 years, nodal manage-
ment and AJCC stage remained significantly predictive of recur-
rence, but HRs became less extreme. In the period of 5 to 10 years,
only AJCC stage remained predictive of recurrence (P  .006).
For time to new primary, there was no evidence of violation of the
proportional hazards assumption (P  .97). Significant predictors
were age (HR, 1.29; P  .001) and date of primary diagnosis after 1992
(HR, 2.21; P  .001; Table 3). AJCC stage was not strongly associated
with time to new primary (P  .053; Appendix Fig A2, online only).
Results of models using a composite outcome of recurrence or new
primary are listed in Appendix Table A1 (online only).
The sensitivity analysis using competing risks models took into
account the impact of deaths resulting from causes other than mela-
noma, new primaries as a competing risk for recurrence, and recur-
rence as a competing risk for new primary. Using these models did not
substantially alter the HRs or conclusions.
Modeled Delay in Diagnosis by Monitoring Schedule
For every 1,000 patients with stage I or II disease beginning
follow-up, 229.2 were observed to develop recurrent melanoma and
61.0 to develop new primary within 10 years. Assuming no unsched-
uled visits prompted by the patient (or family member) detecting an
abnormality, more patients experienced a delay in diagnosis of recur-
rence (Table 4; up to maximum of 1 year) using the less frequent
monitoring schedule (schedule two) compared with that currently
recommended by Australian and New Zealand guidelines (schedule
one), as might be expected, with an estimated 44.9 extra patients per
1,000 experiencing a delay greater than 2 months. More patients also
experienced a delay in diagnosis of new primary (Table 5) with sched-
ule two compared with schedule one, but the absolute difference
between follow-up schedules was smaller (ie, estimated 9.6 extra pa-
tients per 1,000).
If we assume self-detection rates based on published estimates,
use of schedule two rather than schedule one results in only a small
number of additional patients experiencing a delay in recurrence
diagnosis (up to maximum of 3 months; extra 11.3 patients per 1,000
with delay  2 months) and even fewer experiencing a delay in new
primary diagnosis (up to maximum of 6 months; extra 4.9 per 1,000).
The delays in diagnosis of recurrence or new primary considered
together and by AJCC substage are presented in the Appendix (on-
line only).
For every 1,000 patients with stage I or II disease who began
follow-up, approximately 8,044 monitoring visits would have been
needed for schedule one and 5,221 for schedule two. Assuming no loss
Table 1. Summary of Statistics for Recurrences, New Primaries, and








Second primary 240 8.0
First 10 years of follow-up
None 2,128 71.0
Recurrence 687 22.9
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Date of primary diagnosis
 1992 1,593 53.1
 1992 1,405 46.9
Abbreviations: AJCC, American Joint Committee on Cancer; ELND, elective
lymph node dissection; SLNB, sentinel lymph node biopsy.































































Fig 1. Kaplan-Meier curves showing time to recurrence for localized melanoma
according to American Joint Committee on Cancer stage (2009 criteria).
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to follow-up and that patients attended all visits until diagnosis or 10
years, then 19,546 monitoring visits would have been needed for
schedule one and 12,303 for schedule two.
DISCUSSION
We estimated that a larger proportion of patients would experience
some delay in the diagnosis of recurrence or new primary with the
less frequent monitoring strategy (schedule two) compared with
that currently recommended by Australian and New Zealand
guidelines (schedule one). However, the differences between the
two strategies were not large, particularly when we assumed patient
self-detection at previously reported rates of 75% for recurrence3,7
and 50% for new primary.8 It is probable that these differences are
small because of the use of AJCC substage to determine follow-up
frequency in the novel monitoring strategy (schedule two). Cur-
rently, patients with stage IA disease have the same follow-up as
patients with stage IB disease, and all stage II patients have the same
follow-up regardless of substage, despite clear prognostic differ-
ences. On the basis of our modeling, reduction in the number of
patients with a delay in diagnosis, without substantially increasing
the number of visits, might be possible if monitoring frequency was
adjusted according to length of time since treatment, with less
frequent follow-up after the first year (ie, monitoring schedule
combining features of both schedules one and two).
The novel monitoring schedule required far fewer monitoring
visits than are currently recommended. Over 10 years, this would
result in approximately 3,000 fewer visits for every 1,000 newly
diagnosed patients (ie, approximately three fewer visits per patient
over 10 years), assuming dropout rates similar to those observed in
this data set, and more than 7,000 fewer visits for every 1,000 newly
diagnosed patients (average of seven fewer visits per patient over 10
years), if we assume no loss to follow-up. Not only would these
fewer monitoring visits reduce the burden on patients in terms of
time and expense in attendance and possible unnecessary anxiety,
but they would also represent substantial savings for the health
care system.
As might be expected, we found that the risk of recurrence was
greatest in the first year of follow-up, with nodal management and
AJCC substage strongly predictive of recurrence during this time. In
contrast, risk of new primary tended to be constant throughout the
10-year period, with age and date of primary diagnosis strongly pre-
dictive. The finding that risk of new primary was greater for melano-
mas diagnosed after 1992 was unexpected. It may be explained in part
by an increased incidence of melanoma in more recent years12 or a
shorter time to diagnosis (after 1992, a higher proportion of second
primaries were melanoma in situ; data not shown). Age was only
Table 3. Multivariate Cox Proportional Hazards Model for New Primary
Within First 10 Years of Follow-Up in 2,996 Patients With Localized Melanoma
Variable HR 95% CI P
Sex (female v male) 0.80 0.58 to 1.10 .16
Age (per 10-year increase) 1.29 1.17 to 1.44  .001
Primary site (trunk/head and
neck v limb) 1.03 0.75 to 1.42 .85
Nodal management .56
Observation 1
SLNB 1.17 0.77 to 1.77
ELND 0.81 0.46 to 1.45
AJCC stage .053
IA 1
IB 1.12 0.77 to 1.63
IIA 0.56 0.32 to 0.99
IIB 0.70 0.39 to 1.24
IIC 0.95 0.50 to 1.78
Date of primary diagnosis ( 1992 v
 1992 reference group) 2.21 1.55 to 3.16  .001
Abbreviations: AJCC, American Joint Committee on Cancer; ELND, elective
lymph node dissection; HR, hazard ratio; SLNB, sentinel lymph node biopsy.
Table 2. Multivariate Cox Proportional Hazard Models for Recurrence Within First 10 Years of Follow-Up in 2,996 Patients With Localized Melanoma
Variable
First Year Years 1 to 5 Years 5 to 10†
HR 95% CI P HR 95% CI P HR 95% CI P
Sex (female v male) 0.81 0.60 to 1.09 .16 0.79 0.63 to 0.98 .03 0.69 0.42 to 1.11 .12
Age (per 10-year increase) 1.07 0.98 to 1.17 .15 1.12 1.04 to 1.20 .001 1.08 0.92 to 1.26 .36
Primary site (trunk/head and neck v limb) 1.45 1.07 to 1.97 .016 1.07 0.86 to 1.33 .54 0.77 0.49 to 1.23 .28
Nodal management  .001  .001 .088
Observation 1 1 1
SLNB 0.40 0.25 to 0.63 0.50 0.35 to 0.71 1.60 0.73 to 3.53
ELND 0.31 0.19 to 0.50 0.50 0.37 to 0.68 0.58 0.30 to 1.11
AJCC stage  .001  .001 .006
IA 1 1 1
IB 2.85 1.33 to 6.11 3.47 2.18 to 5.51 2.21 1.02 to 4.76
IIA 11.95 5.60 to 25.50 8.98 5.53 to 14.60 3.93 1.57 to 9.85
IIB 21.94 10.38 to 46.38 11.18 6.82 to 18.33 5.06 1.96 to 13.02
IIC 28.25 13.08 to 61.01 12.18 7.15 to 20.75 4.94 1.58 to 15.42
Date of primary diagnosis ( 1992 v
 1992 reference group) 1.05 0.77 to 1.43 .74 1.12 0.88 to 1.44 .35 0.91 0.49 to 1.69 .76
Abbreviations: AJCC, American Joint Committee on Cancer; ELND, elective lymph node dissection; HR, hazard ratio; SLNB, sentinel lymph node biopsy.
Estimates for follow-up years 1 to 5 are for 2,240 patients.
†Estimates for follow-up years 5 to 10 are for 961 patients.
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predictive of recurrence 1 to 5 years after diagnosis. However, AJCC
stage was still by far the dominant predictor of recurrence, so there
would be little added benefit in developing age-specific follow-
up strategies.
Nodal management at MIA changed with the introduction of
SLNB in 1992. A significant difference in time to recurrence was found
for patients diagnosed before and during 1992 compared with those
diagnosed after 1992. This difference with time was no longer signifi-
cant when nodal management was included in the model. Clinically
staged patients are more at risk for developing regional lymph node
recurrence and are therefore potentially more likely to experience a
delay in diagnosis. A reduction in follow-up frequency might be safe
for pathologically staged patients but not as safe for (higher risk)
clinically staged patients. However, because nodal staging by SLNB
protects against early recurrence, and many more patients now un-
dergo SLNB, this should not affect our conclusions.
Limitations of the study include uncertainty as to actual time of
recurrence or new primary melanoma development for some patients in
the data set, especially those whose diagnosis was not made until they
attended a scheduled follow-up visit. However, monitoring schedules
were usually more frequent in the study timeframe than they are now,
which, together with the high frequency of self-detection, means we can
expect therecordeddateofdiagnosis tobereasonablyaccurate.Sensitivity
analysis of the self-detection rate showed that the number of patients with
a delay in diagnosis of recurrence or new primary decreased almost lin-
early as the self-detection rate increased. Patients and clinicians may have
otherobjectivesforfollow-upvisitsinadditiontodetectionofrecurrentor
new melanoma13; for example, patients want reassurance and the oppor-
tunity to ask questions.14 These objectives may be more effectively met by
fewer visits with a more focused approach to addressing these needs. We
have only evaluated 10 years of follow-up after initial treatment and are
thereforeunable toextrapolatehowmonitoringstrategieswouldperform
beyondthis.Manyreportshavesuggestedthatrecurrencetendstoplateau
at low rates after the first 10 years.9 Theoretic modeling does not account
for patient adherence to the monitoring schedule; indeed, it is unclear
whetheradherencetofollow-upwouldincreaseordecrease if thenumber
of follow-up visits were reduced, an issue that requires more empirical
study.Finally, therearelikelytobeasmallnumberoftruestageIIIpatients
misclassified as stage II when observation is the nodal management strat-
egy, but this is unlikely to affect the overall conclusions, and if anything,
the results presented would be biased toward showing greater benefit
from a more frequent monitoring schedule, because such patients are
more likely to develop recurrence.
Our study does not address any difference in the ultimate benefit
of monitoring, assessed, for example, by incremental loss in life years
for each monitoring visit foregone. To do this would require a suitably
powered randomized controlled trial.
Table 4. Modeled No. of Patients With Delay in Recurrence Diagnosis per 1,000 Patients During 10 Years of Follow-Up
Delay Threshold
(months)
Scheduled Visits Only Scheduled and Unscheduled Visits†
Schedule 1 Schedule 2 Schedule 1 Schedule 2
No. 95% CI No. 95% CI No. 95% CI No. 95% CI
 1 169.8 160.1 to 179.5 192.8 183.5 to 201.8 42.5 38.7 to 46.0 48.3 45.0 to 51.4
 2 113.5 104.1 to 123.1 158.4 148.4 to 167.8 28.4 24.0 to 32.7 39.7 35.4 to 43.7
 3 52.7 45.2 to 60.4 127.7 118.4 to 137.4 N/A N/A
 6 16.0 11.7 to 20.7 65.0 57.0 to 73.0 N/A N/A
 9 9.6 6.3 to 13.3 34.3 28.4 to 40.7 N/A N/A
 12 N/A N/A N/A N/A
Abbreviation: N/A, not applicable (zero according to either follow-up schedule used or assumption about self-detection).
Assumes no unscheduled visits because of self-detection.
†Assumes unscheduled visits in 75% of patients because of self-detection with no delay in diagnosis and maximum delay in diagnosis of 3 months for other
patients before scheduled visit or self-detection.
Table 5. Modeled No. of Patients With Delay in New Primary Diagnosis per 1,000 Patients During 10 Years of Follow-Up
Delay Threshold
(months)
Only Scheduled Visits Scheduled and Unscheduled Visits†
Schedule 1 Schedule 2 Schedule 1 Schedule 2
No. 95% CI No. 95% CI No. 95% CI No. 95% CI
 1 44.1 37.4 to 51.0 47.4 40.4 to 54.7 22.1 19.3 to 24.7 23.8 21.0 to 26.4
 2 34.1 28.0 to 40.4 43.7 37.0 to 50.7 17.1 14.0 to 20.3 22.0 19.0 to 24.7
 3 26.1 20.7 to 31.7 39.1 32.7 to 45.7 13.1 10.0 to 16.3 19.6 16.7 to 22.7
 6 6.7 4.0 to 9.7 23.0 17.8 to 28.4 N/A N/A
 9 3.3 1.3 to 5.7 11.7 8.0 to 15.7 N/A N/A
 12 N/A N/A N/A N/A
Abbreviation: N/A, not applicable (zero according to either follow-up schedule used or assumption about self-detection).
Assumes no unscheduled visits because of self-detection.
†Assumes unscheduled visits in 50% of patients because of self-detection with no delay in diagnosis and maximum delay in diagnosis of 6 months for other
patients before scheduled visit or self detection.
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Strengths of this study include the large number of patients
included with a spectrum of disease likely to be representative of a
clinical population of patients treated for localized cutaneous mela-
noma. Included patients all had detailed pathology results, and we
were able to accurately assign AJCC substaging according to the most
recent classification published in 2009. We used rigorous statistical
methods for the prognostic model and for estimating the delay in
diagnosis for different monitoring strategies.
In summary, current guidelines on the frequency of follow-up
after treatment for localized melanoma probably provide rather small
gains (in terms of earlier diagnosis of recurrence or new primary) at
the expense of a large number of additional clinic visits. A less frequent
monitoring schedule, such as that proposed in a former MIA publica-
tion9 and further investigated in the MELFO study,4 may decrease
unnecessary visits substantially, with only a small consequent delay in
the detection of recurrent or new primary melanoma.
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